Fennec Pharmaceuticals Inc. (FENC) financial statements (2020 and earlier)
Company profile
| Business Address |
PO BOX 13628 RESEARCH TRIANGLE PARK, NC 27709 |
| State of Incorp. | BC |
| Fiscal Year End | December 31 |
| SIC | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 9/30/2019 TTM | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 15 | 23 | 28 | 4 | 1 | 2 | 2 | ||
| Cash and cash equivalents | 15 | 23 | 28 | 4 | 1 | 2 | 2 | ||
| Prepaid expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Other current assets | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Total current assets: | 16 | 23 | 28 | 4 | 1 | 2 | 2 | ||
| Noncurrent Assets | |||||||||
| Other undisclosed noncurrent assets | 0 | ||||||||
| Total noncurrent assets: | 0 | ||||||||
| TOTAL ASSETS: | 16 | 23 | 28 | 4 | 1 | 2 | 2 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 1 | 2 | 1 | 0 | 0 | 0 | 0 | ||
| Accounts payable | 1 | 1 | 1 | 0 | 0 | 0 | 0 | ||
| Accrued liabilities | 0 | 1 | 1 | 0 | 0 | 0 | 0 | ||
| Derivative instruments and hedges, liabilities | 0 | 0 | 0 | 1 | 3 | ||||
| Total current liabilities: | 1 | 2 | 2 | 0 | 0 | 2 | 3 | ||
| Noncurrent Liabilities | |||||||||
| Total liabilities: | 1 | 2 | 2 | 0 | 0 | 2 | 3 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent, including: | 15 | 21 | 27 | 4 | 1 | 1 | (1) | ||
| Common stock | 106 | 106 | 103 | 75 | 69 | 69 | 67 | ||
| Additional paid in capital | 48 | 45 | 44 | 42 | 42 | 42 | 39 | ||
| Accumulated other comprehensive income | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||
| Accumulated deficit | (140) | (131) | (121) | (114) | (112) | (111) | |||
| Other undisclosed stockholders' equity attributable to parent | (109) | ||||||||
| Total stockholders' equity: | 15 | 21 | 27 | 4 | 1 | 1 | (1) | ||
| TOTAL LIABILITIES AND EQUITY: | 16 | 23 | 28 | 4 | 1 | 2 | 2 | ||
Income statement (P&L) ($ in millions)
| 9/30/2019 TTM | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | ||
|---|---|---|---|---|---|---|---|---|
| Operating expenses | (12) | (10) | (7) | (3) | (2) | (3) | (2) | |
| Other undisclosed operating loss | (0) | |||||||
| Operating loss: | (12) | (10) | (7) | (3) | (2) | (3) | (2) | |
| Nonoperating income (expense) | 0 | 1 | (0) | 0 | 1 | 1 | 4 | |
| Investment income, nonoperating | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Other nonoperating income (expense) | (0) | 0 | (0) | (0) | (0) | |||
| Interest and debt expense | (0) | |||||||
| Net income (loss): | (12) | (10) | (7) | (3) | (1) | (2) | 2 | |
| Other undisclosed net income attributable to parent | 0 | |||||||
| Net income (loss) available to common stockholders, diluted: | (12) | (10) | (7) | (3) | (1) | (2) | 2 | |
Comprehensive Income ($ in millions)
| 9/30/2019 TTM | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (12) | (10) | (7) | (3) | (1) | (2) | 2 | |
| Comprehensive income (loss), net of tax, attributable to parent: | (12) | (10) | (7) | (3) | (1) | (2) | 2 | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.